Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Prospective Randomized Trial Protocol for Duration of Post-Operative Tazocin Treatment After Whipple Operation

9 novembre 2026 aggiornato da: Tel-Aviv Sourasky Medical Center

Pancreaticoduodenectomy (Whipple procedure) is associated with substantial postoperative morbidity, mainly infectious complications and postoperative pancreatic fistula. Perioperative antibiotic prophylaxis is routine, but the optimal strategy for postoperative antibiotic administration is unclear, and practice varies between surgeons.

The objective of this study is to determine whether the duration of postoperative piperacillin-tazobactam (24 hours versus 5 days) affects postoperative infectious outcomes in patients undergoing pancreaticoduodenectomy.

This is a single-center, prospective, randomized clinical trial in adults undergoing open or minimally invasive (robotic) pancreaticoduodenectomy. All consented patients receive perioperative piperacillin-tazobactam according to institutional practice. After the operation is completed, patients who underwent pancreaticoduodenectomy and remain eligible are randomized by a computerized system, stratified by presence of a preoperative biliary stent and by surgical approach, to postoperative antibiotic treatment for 24 hours or 5 days.

The primary endpoint is the rate of postoperative infectious complications, comprising superficial wound infection, deep (fascial) surgical site infection, and intra-abdominal infection, defined according to CDC criteria, [within 30 days after surgery]. Participation does not change surgical technique, length of hospitalization, or routine follow-up.

As an exploratory component, intraoperative bile cultures are collected to describe biliary microbial profiles and antibiotic resistance patterns.

The study aims to provide high-quality evidence to guide postoperative antibiotic management and support more rational use of broad-spectrum antibiotics in pancreatic surgery.

Panoramica dello studio

Descrizione dettagliata

BACKGROUND AND RATIONALE

Pancreaticoduodenectomy (Whipple procedure) is a standard surgical treatment for benign and malignant diseases of the pancreatic head and periampullary region. The operation carries high morbidity and mortality. The most common complications are postoperative infections and pancreatic fistula, occurring in approximately 30-50% of patients. These complications reduce quality of life, limit the ability to complete adjuvant chemotherapy, and are associated with lower overall survival.

Biliary infection, particularly after preoperative biliary stenting, is a major contributor to postoperative infections. Stenting alters the biliary microbial profile and often leads to colonization with organisms associated with higher rates of postoperative infection and pancreatic fistula. These organisms frequently show resistance to standard prophylactic antibiotics, which highlights the importance of matching antibiotic regimens to the patient's microbial profile.

Perioperative antibiotic prophylaxis is routinely administered during pancreatic surgery. However, continuation of antibiotics after surgery varies between clinicians and is left to the surgeon's discretion, without a defined protocol. Recent studies indicate that broad-spectrum antibiotics such as piperacillin-tazobactam (Tazocin) are superior to cephalosporins in reducing infections after Whipple surgery, particularly in patients with a preoperative biliary stent. However, the optimal duration of therapy remains unclear. Longer treatment may further reduce infections in high-risk populations, but raises concerns regarding antimicrobial resistance, adverse effects, and cost.

OBJECTIVE

To compare the efficacy of short-course (24 hours) versus extended (5 days) postoperative piperacillin-tazobactam in reducing infections after pancreaticoduodenectomy. By optimizing antibiotic duration, the study seeks to balance infection prevention and clinical outcomes against responsible antibiotic stewardship, and to propose a new standard for managing patients undergoing this operation.

STUDY DESIGN

Single-center, prospective, randomized, open-label clinical trial. A total of 200 participants will be enrolled at Tel Aviv Sourasky Medical Center, undergoing pancreaticoduodenectomy by an open or minimally invasive (robotic) approach.

Written informed consent is obtained before surgery. All participants receive piperacillin-tazobactam before skin incision and during surgery. After the operation is completed, patients in whom pancreaticoduodenectomy was successfully completed and who remain eligible are randomly assigned, using a computerized system, to one of two groups. Randomization is stratified by:

  • Presence or absence of a preoperative biliary stent
  • Surgical approach (open versus minimally invasive/robotic)

These factors were selected because of their potential impact on postoperative infectious risk. Patients in whom pancreaticoduodenectomy is not performed are not randomized and are not included in the study.

  • Group 1: piperacillin-tazobactam for 5 days after the end of surgery
  • Group 2: piperacillin-tazobactam for 24 hours after the end of surgery

Because the antibiotic is ordered as a visible medical order and given intravenously during hospitalization, participants and investigators are aware of group allocation. Participation does not prolong the operation or the usual hospital stay.

PARTICIPANT SELECTION AND CONSENT

Eligible adults scheduled for Whipple surgery are approached in the preoperative clinic or during admission before surgery. Written informed consent is obtained after a full face-to-face explanation, with time for questions, using a digital consent process, or a paper form if the patient declines digital signing or technical problems occur.

Inclusion criteria:

  • Age 18 years or older
  • Scheduled for pancreaticoduodenectomy (Whipple procedure), open or minimally invasive (robotic), at Tel Aviv Sourasky Medical Center
  • Ability to provide informed consent
  • Completion of pancreaticoduodenectomy, confirmed at the end of the operation

Exclusion criteria:

  • Age under 18 years, pregnancy, or lack of decision-making capacity
  • Known hypersensitivity to penicillins, piperacillin-tazobactam, cephalosporins, or beta-lactamase inhibitors
  • Contraindication to piperacillin-tazobactam based on prior microbiological culture results or antibiotic resistance profiles

Removal from the study (before or after randomization):

  • Preoperative microbiological findings requiring an antibiotic regimen other than piperacillin-tazobactam
  • Deviation from the pre-agreed antibiotic protocol or from the recommended postoperative algorithm
  • Reoperation (surgical revision)

INTERVENTION AND DOSING

Intraoperative: piperacillin-tazobactam 4.5 g within 60 minutes before incision, with additional doses every 2-4 hours until the end of surgery, adjusted for renal function.

Postoperative: 4.5 g three times daily, or a reduced dose according to renal function, for 5 days (Group 1) or 24 hours (Group 2).

POSTOPERATIVE CARE AND FOLLOW-UP

Inpatient follow-up is the routine for Whipple surgery: daily physician rounds with history, vital signs, physical examination, drain output, and review of laboratory tests and imaging. Blood tests are routine on postoperative days 1 and 2, and thereafter at the discretion of the treating team. Decisions on CT imaging and on additional antibiotic treatment, regardless of study group, follow the algorithm-based care of the Dutch Pancreatic Cancer Group, agreed in advance by all pancreatic surgeons.

After discharge, participants are followed in the surgical clinic at 1, 3, 6, and 12 months after surgery, and annually thereafter.

OUTCOME MEASURES

Primary endpoint: rate of surgical site infection (SSI) within 30 days of surgery, comprising superficial incisional, deep incisional, and organ/space SSI according to CDC definitions.

Secondary endpoints:

  1. Overall postoperative complication rate
  2. Postoperative pancreatic fistula
  3. Microbial profile and antibiotic resistance at surgery (bile) and afterward
  4. Antibiotic-related adverse events and complications (e.g., Clostridioides difficile infection)
  5. Need for invasive intervention after surgery
  6. Need for reoperation
  7. Overall survival

DATA COLLECTION

Data are collected in coded form, with the coding key held separately by the principal investigator, and are not shared outside the hospital. Collected data include demographics; preoperative clinical variables (BMI, comorbidities, ASA score, biliary stent or drainage, neoadjuvant therapy, pathology); operative variables (approach, duration, pancreatic texture, duct size, blood loss, vascular reconstruction, bile culture results); postoperative course (length of stay, infections, pancreatic fistula grade, C. difficile infection, imaging, interventions, reoperation, other infectious and non-infectious complications); and follow-up to one year (late complications, cancer recurrence, date of last visit or death).

STATISTICAL ANALYSIS

Overall infection rate, infection rate by subtype, and pancreatic fistula rate are compared between the groups using the chi-square test. The same test is used for reoperation, invasive intervention, other postoperative complications, and C. difficile infection. Common bacteria and antibiotic sensitivity profiles are described. Cancer recurrence and overall survival are compared using Kaplan-Meier curves.

STUDY SIGNIFICANCE

This trial compares two durations of postoperative piperacillin-tazobactam in a standardized, randomized setting. The results are expected to guide postoperative antibiotic management, reduce infectious morbidity after pancreaticoduodenectomy, and support more rational use of broad-spectrum antibiotics.

Tipo di studio

Interventistico

Iscrizione (Stimato)

200

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israele, 6423906
        • Reclutamento
        • Department of Hepatobiliary Surgery, Tel Aviv Sourasky Medical Center Tel Aviv, Israel
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18 years or older
  • Scheduled for pancreaticoduodenectomy (Whipple procedure), open or minimally invasive (robotic), at Tel Aviv Sourasky Medical Center
  • Ability to provide informed consent
  • Completion of pancreaticoduodenectomy, confirmed at the end of the operation

Exclusion Criteria:

  • Age under 18 years, pregnancy, or lack of decision-making capacity
  • Known hypersensitivity to penicillins, piperacillin-tazobactam, cephalosporins, or beta-lactamase inhibitors
  • Contraindication to piperacillin-tazobactam based on prior microbiological culture results or antibiotic resistance profiles

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Piperacillin-tazobactam for 5 days

Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 5 days after the end of surgery, in addition to perioperative dosing before incision and during surgery.

Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.

Altri nomi:
  • Zosina
  • Tazocin
Sperimentale: Piperacillin-tazobactam for 24 hours

Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 24 hours after the end of surgery, in addition to perioperative dosing before incision and during surgery.

Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.

Altri nomi:
  • Zosina
  • Tazocin

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of surgical site infection (SSI) after pancreaticoduodenectomy
Lasso di tempo: Within 30 days after surgery

Proportion of participants with surgical site infection, comprising superficial incisional SSI, deep incisional SSI, and organ/space SSI (intra-abdominal infection), as defined by the CDC National Healthcare Safety Network criteria.

Within 30 days after surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall early postoperative complication rate
Lasso di tempo: Within 30 days after surgery

roportion of participants with any postoperative complication, including pancreatic fistula, infectious complications other than surgical site infection (urinary tract infection, pneumonia, line sepsis), hemorrhage (requiring transfusion or intervention such as angiography), delayed gastric emptying, ileus or early small bowel obstruction, chyle leak, acute kidney injury, venous thromboembolism, and acute coronary syndrome (STEMI/non-STEMI).

Within 30 days after surgery
Postoperative pancreatic fistula
Lasso di tempo: Within 30 days after surgery

Proportion of participants who develop a postoperative pancreatic fistula, graded A, B, or C according to the International Study Group on Pancreatic Fistula (ISGPS) definition.

Within 30 days after surgery
Late postoperative complications
Lasso di tempo: Between 30 days and 1 year after surgery

Proportion of participants with complications occurring after the early postoperative period (beyond 30 days), including: anastomotic stricture (biliary, pancreatic-enteric, or gastro/duodeno-enteric); anastomotic or marginal ulcer; late hemorrhage or pseudoaneurysm; delayed intra-abdominal collection or abscess; delayed or recurrent cholangitis; incisional hernia; small bowel obstruction or internal hernia; exocrine pancreatic insufficiency requiring enzyme replacement; new-onset or worsening diabetes mellitus; chronic diarrhea, malabsorption, or weight loss; portal or mesenteric vein thrombosis.

Between 30 days and 1 year after surgery
Need for invasive intervention after surgery
Lasso di tempo: Within 30 days after surgery

Proportion of participants who require an invasive intervention after the operation (for example, percutaneous drainage or an angiographic procedure), excluding return to the operating room.

Within 30 days after surgery
Early reoperation
Lasso di tempo: Within 30 days after surgery

Proportion of participants who require a return to the operating room for surgical revision or reintervention after the index operation, for any cause related to the index operation, during the early postoperative period.

Within 30 days after surgery
Late reoperation
Lasso di tempo: Between 30 days and 1 year after surgery

Proportion of participants who require a return to the operating room for surgical revision or reintervention after the early postoperative period (beyond 30 days), for any cause related to the index operation.

Between 30 days and 1 year after surgery
Antibiotic-related adverse events, including Clostridioides difficile infection
Lasso di tempo: Within 60 days after surgery

Proportion of participants with adverse events and complications attributable to antibiotic administration, including Clostridioides difficile infection (CDT).

Within 60 days after surgery
Microbial profile and antibiotic resistance
Lasso di tempo: At surgery (bile cultures) and up to 60 days after surgery

Organisms isolated and their antibiotic susceptibility and resistance profiles, from intraoperative bile cultures and from postoperative blood or other body fluid cultures taken when clinically indicated. Compared between participants with and without a preoperative biliary stent and between study groups.

At surgery (bile cultures) and up to 60 days after surgery
Overall survival
Lasso di tempo: Up to 5 years after surgery

Time from the date of surgery to death from any cause. Participants alive at last follow-up are censored at the date of last visit. Compared between study groups using Kaplan-Meier curves.

Up to 5 years after surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 marzo 2025

Completamento primario (Stimato)

31 dicembre 2028

Completamento dello studio (Stimato)

31 dicembre 2029

Date di iscrizione allo studio

Primo inviato

9 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi